Medistim Valuation Multiples

Medistim Overview

About Medistim

Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.

Founded

1984

HQ

Employees

154

Website

medistim.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $76M

EBITDA: $23M

EV

$436M

Valuation Multiples

Multiples.vc

Start free trial

Medistim Financials

Medistim reported last 12-month revenue of $76M and EBITDA of $23M.

In the same LTM period, Medistim generated $62M in gross profit, $23M in EBITDA, and $17M in net income.

Medistim P&L

In the most recent fiscal year, Medistim reported revenue of $75M and EBITDA of $24M.

Medistim expects next 12-month revenue of XXX and NTM EBITDA of XXX

Medistim Stock Performance

Medistim has current market cap of $455M, and enterprise value of $436M.

Medistim's stock price is $24.88.

Medistim Valuation Multiples

Medistim trades at 5.7x EV/Revenue multiple, and 18.7x EV/EBITDA.

Medistim Financial Valuation Multiples

As of April 19, 2026, Medistim has market cap of $455M and EV of $436M.

Equity research analysts estimate Medistim's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Medistim has a P/E ratio of 26.9x.

Medistim Margins & Growth Rates

Medistim's revenue in the last 12 month grew by 10%.

Medistim's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.

Medistim's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medistim's rule of X is 54% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Medistim Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Medistim M&A Activity

Medistim acquired XXX companies to date.

Last acquisition by Medistim was on XXXXXXXX, XXXXX. Medistim acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Medistim Investment Activity

Medistim invested in XXX companies to date.

Medistim made its latest investment on XXXXXXXX, XXXXX. Medistim invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).